Clinical research ·
A phase 3 study puts faster-onset botulinum toxin E back into the glabellar-line conversation.
A placebo-controlled phase 3 study published July 24, 2026 found trenibotulinumtoxinE improved moderate-to-severe glabellar lines quickly, with effects observed at hour 8, peaking at day 7 and largely returning by day 21. The study is about rapid onset and short duration in a controlled setting, not proof that a shorter-acting toxin is the right fit for every forehead or frown-line plan.Source lens · Phase 3 placebo-controlled trial - Rapid onset and short duration still need individualized treatment planning- trenibotulinumtoxinE
- glabellar lines
- neuromodulator
- phase 3
How this connects to Dagan MD care
BOTOX CosmeticCompare faster-onset neuromodulator data with the longer-established treatment options already in common use.↗Injectables ReframedSee how wrinkle treatment fits into a broader anatomy-led injectables plan rather than a one-area decision.↗
